top of page
3D_bacterial chain.jpg

Pioneering Precision Lysin Therapeutics

At Obulytix, we develop Precision Lysin Therapeutics (PLTs), a new class of targeted biologics, as next-generation antibiotics, ​engineered to selectively kill bacteria without fueling antimicrobial resistance.

Antibiotics are essential to today’s healthcare system. They make safe surgery possible, support cutting-edge cancer treatments, and help fight life-threatening infections. But their effectiveness is rapidly declining due to the rise of antimicrobial resistance (AMR).

As bacteria evolve to resist existing drugs, routine medical procedures and lifesaving therapies are increasingly at risk. Conventional antibiotics are no longer enough to combat multidrug-resistant strains. To safeguard the future of medicine, we urgently need innovative solutions—new treatments capable of overcoming resistance and restoring our ability to fight infection.

CHI_7515-Enhanced-NR.jpg

Building the future of antibiotics

"A post-antibiotic era means, in effect, an end to modern medicine as we know it. Things as common as strep throat or a child's scratched knee could once again kill"

Margaret Chan, former Director-General of the World Health Organization

Our latest news

Dots - pink.png

Join the Precision Lysin Therapeutics revolution in infection control.

bottom of page